bluuebunny/crossref_metadata_2025 huggingface dataset:
Data from Performance of Statistical and Machine Learning Risk Prediction Models for Surveillance Benefits and Failures in Breast Cancer Survivors
Authors: Su Yu-Ru , Buist Diana S.M. , Lee Janie M. , Ichikawa Laura , Miglioretti Diana L. , Bowles Erin J. Aiello , Wernli Karen J. , Kerlikowske Karla , Tosteson Anna , Lowry Kathryn P. , Henderson Louise M. , Sprague Brian L. , Hubbard Rebecca A.
Published: April 2023

AbstractBackground:
Machine learning (ML) approaches facilitate risk prediction model development using high-dimensional predictors and higher-order interactions at the cost of model interpretability and transparency. We compared the relative predictive performance of statistical and ML models to guide modeling strategy selection for surveillance mammography outcomes in women with a personal history of breast cancer (PHBC).
Methods:
We cross-validated seven risk prediction models for two surveillance outcomes, failure (breast cancer within 12 months of a negative surveillance mammogram) and benefit (surveillance-detected breast cancer). We included 9,447 mammograms (495 failures, 1,414 benefits, and 7,538 nonevents) from years 1996 to 2017 using a 1:4 matched case–control samples of women with PHBC in the Breast Cancer Surveillance Consortium. We assessed model performance of conventional regression, regularized regressions (LASSO and elastic-net), and ML methods (random forests and gradient boosting machines) by evaluating their calibration and, among well-calibrated models, comparing the area under the receiver operating characteristic curve (AUC) and 95% confidence intervals (CI).
Results:
LASSO and elastic-net consistently provided well-calibrated predicted risks for surveillance failure and benefit. The AUCs of LASSO and elastic-net were both 0.63 (95% CI, 0.60–0.66) for surveillance failure and 0.66 (95% CI, 0.64–0.68) for surveillance benefit, the highest among well-calibrated models.
Conclusions:
For predicting breast cancer surveillance mammography outcomes, regularized regression outperformed other modeling approaches and balanced the trade-off between model flexibility and interpretability.
Impact:
Regularized regression may be preferred for developing risk prediction models in other contexts with rare outcomes, similar training sample sizes, and low-dimensional features.
Data from The Intersectionality between Race, Ethnicity, and Residential-Level Socioeconomic Status in Disparities of Head and Neck Cancer Outcomes: A SEER Study
Authors: Karanth Shama D. , Akinyemiju Tomi , Walker Courtney J. , Yang Danting , Migliorati Cesar A. , Yoon Hyung-Suk , Hong Young-Rock , Washington Caretia J. , Lattimore Chayil , Fredenburg Kristianna M. , Braithwaite Dejana
Published: April 2023

AbstractBackground:
Head and neck cancer (HNC) mortality differs by race, ethnicity, and socioeconomic status (SES). However, it is unclear whether the relationship between race/ethnicity and HNC-specific mortality varies according to the residence-level SES.
Methods:
Data from the Surveillance Epidemiology and End Results database included participants with primary HNC between 2006 and 2017 (followed through 2018) to assess the joint association of race/ethnicity and census-tract level SES Yost-index groups (quintiles) with all-cause and HNC-specific mortalities. Relative survival rates at 1, 5, and 10 years were calculated. Multivariable Cox proportional hazard regression models estimated hazard-ratios and 95% confidence intervals for all-cause mortality, and Fine-Gray subdistribution hazard models for HNC-specific mortality. Cumulative incidence curves for HNC-specific deaths were estimated.
Results:
76,095 patients were included in the analysis: 63.2% were <65 years, 73.4% male, and 11.3% non-Hispanic (NH) Black. Most patients (58.3%) were diagnosed at regional or distant stages and 20.6% died of HNC. The five-year relative survival rate increased with SES group, with 51.6% in the lowest SES group, and 74.1% in the highest SES group. NH-Black patients had higher risk of all-cause and HNC-specific mortality than NH-White patients, regardless of the SES group. NH-Asian/Pacific Islander and Hispanic patients had higher risk of HNC-specific mortality in some SES groups.
Conclusions:
NH-Black patients of all SES strata had significantly worse outcomes. Other factors, such as healthcare quality, may be associated with persistent disparities.
Impact:
The study highlights the persistence of significant racial disparities in HNC survival across socioeconomic categories. There is need to consider additional factors underlying these disparities.
Data from Periodontal and Other Oral Bacteria and Risk of Lung Cancer in the Atherosclerosis Risk in Communities (ARIC) Study
Authors: Zhou Baijun , Lu Jiayun , Beck James D. , Moss Kevin L. , Prizment Anna E. , Demmer Ryan T. , Porosnicu Rodriguez Kori A. , Joshu Corinne E. , Michaud Dominique S. , Platz Elizabeth A.
Published: April 2023

AbstractBackground:
Evidence suggests that periodontal disease is associated with increased lung cancer risk, but whether periodontal pathogens are explanatory is unknown. We prospectively studied associations of prediagnostic circulating antibodies with oral bacteria and of periodontal bacteria in subgingival plaque with lung cancer.
Methods:
We included 4,263 cancer-free participants in the Atherosclerosis Risk in Communities study with previously measured serum IgG antibodies to 18 oral bacteria. In 1,287 participants for whom subgingival plaque was collected, counts for 8 periodontal bacteria were previously measured. Incident lung cancers (N = 118) were ascertained through 2015 (median follow-up = 17.5 years). We used Cox regression to estimate multivariable-adjusted associations, including for sums of antibodies to orange (C. rectus, F. nucleatum, P. intermedia, P. micra, and P. nigrescens) and red (P. gingivalis, T. forsythensis, and T. denticola) complex bacteria.
Results:
Orange complex bacteria antibodies were positively associated with lung cancer [per IQR hazard ratios (HR) = 1.15; 95% confidence intervals (CI), 1.02–1.29], which was stronger in men (HR = 1.27, 95% CI 1.08–1.49), and explained by P. intermedia and P. nigrescens (HR = 1.15; 95% CI, 1.04–1.26). Suggestive positive associations with lung cancer (N = 40) were observed for F. nucleatum, A. actinomycetemcomitans, and P. gingivalis counts. Significant positive associations were found for the count to antibody ratio for P. intermedia and P. gingivalis.
Conclusions:
We identified positive associations with lung cancer for oral bacteria, especially orange complex that are moderately pathogenic for periodontal disease.
Impact:
This prospective study supports the need for more research on periodontal bacteria in lung cancer etiology. If associations are supported, this may inform novel lung cancer prevention strategies.
Figure S7 from An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell Carcinomas
Authors: Lu Xiaofan , Vano Yann , Helleux Alexandra , Su Xiaoping , Lindner Véronique , Davidson Guillaume , Mouawad Roger , Spano Jean-Philippe , Rouprêt Morgan , Elaidi Reza , Compérat Eva , Verkarre Virginie , Sun Chengming , Chevreau Christine , Bennamoun Mostefa , Lang Hervé , Tricard Thibault , Cheng Wenxuan , Xu Li , Davidson Irwin , Yan Fangrong , Fridman Wolf Herman , Sautes-Fridman Catherine , Oudard Stéphane , Malouf Gabriel G.
Published: April 2023

Figure S7. a) Heatmap showing the methylation profiles of two 𝑇𝐸𝐷 phenotypes by unsupervised clustering of enhancer probes in the Beuselinck cohort in which 102 patients developed metastatic ccRCC and were treated with the first-line TKI of sunitinib. Kaplan-Meier survival curves showing the survival rate of two 𝑇𝐸𝐷 phenotypes in view of b) OS and c) PFS.
Figure S4 from An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell Carcinomas
Authors: Lu Xiaofan , Vano Yann , Helleux Alexandra , Su Xiaoping , Lindner Véronique , Davidson Guillaume , Mouawad Roger , Spano Jean-Philippe , Rouprêt Morgan , Elaidi Reza , Compérat Eva , Verkarre Virginie , Sun Chengming , Chevreau Christine , Bennamoun Mostefa , Lang Hervé , Tricard Thibault , Cheng Wenxuan , Xu Li , Davidson Irwin , Yan Fangrong , Fridman Wolf Herman , Sautes-Fridman Catherine , Oudard Stéphane , Malouf Gabriel G.
Published: April 2023

Figure S4. Focal copy number deletion identified by the GISTIC algorithm for a) 𝑇𝐸𝐷+ and b) 𝑇𝐸𝐷−, respectively, in the immunotherapy arm of the BIONIKK cohort.
Supplementary table 3 from Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic Melanoma
Authors: Tobin Richard P. , Cogswell Dasha T. , Cates Victoria M. , Davis Dana M. , Borgers Jessica S.W. , Van Gulick Robert J. , Katsnelson Elizabeth , Couts Kasey L. , Jordan Kimberly R. , Gao Dexiang , Davila Eduardo , Medina Theresa M. , Lewis Karl D. , Gonzalez Rene , McFarland Ross W. , Robinson William A. , McCarter Martin D.
Published: April 2023

Establishing recommended phase II dose (RP2D) and dose limiting toxicities (DLTs)
Figure S7 from Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer
Authors: Chopra Shalini , Trepka Kai , Sakhamuri Sasank , Carretero-González Alberto , Zhu Jun , Egusa Emily , Zhou Jie , Leung Kevin , Zhao Ning , Hooshdaran Nima , Feng Felix Y. , Wells James A. , Chou Jonathan , Evans Michael J.
Published: April 2023

A summary of the data from saturation binding assays used to calculate Bmax and receptor number per cell for bladder cancer cell lines. The data are representative of two independent assays. Data are reported as mean ± standard deviation.
Figure S2 from Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer
Authors: Chopra Shalini , Trepka Kai , Sakhamuri Sasank , Carretero-González Alberto , Zhu Jun , Egusa Emily , Zhou Jie , Leung Kevin , Zhao Ning , Hooshdaran Nima , Feng Felix Y. , Wells James A. , Chou Jonathan , Evans Michael J.
Published: April 2023

CDCP1 mRNA expression by clinical stage in the Seiler dataset. p=0.12 by Kruskal-Wallis test.
Data from An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell Carcinomas
Authors: Lu Xiaofan , Vano Yann , Helleux Alexandra , Su Xiaoping , Lindner Véronique , Davidson Guillaume , Mouawad Roger , Spano Jean-Philippe , Rouprêt Morgan , Elaidi Reza , Compérat Eva , Verkarre Virginie , Sun Chengming , Chevreau Christine , Bennamoun Mostefa , Lang Hervé , Tricard Thibault , Cheng Wenxuan , Xu Li , Davidson Irwin , Yan Fangrong , Fridman Wolf Herman , Sautes-Fridman Catherine , Oudard Stéphane , Malouf Gabriel G.
Published: April 2023

AbstractPurpose:
Immune checkpoint inhibitors (ICI) have revolutionized the treatment of patients with clear-cell renal cell carcinomas (ccRCC). Although analyses of transcriptome, genetic alterations, and the tumor microenvironment (TME) have shed light into mechanisms of response and resistance to these agents, the role of epigenetic alterations in this process remains fully unknown.
Experimental Design:
We investigated the methylome of six ccRCC cohorts as well as one cell line dataset. Of note, we took advantage of the BIONIKK trial aiming to tailor treatments according to Paris Descartes 4-gene expression subgroups, and performed Illumina EPIC profiling for 46 samples related to patients treated with ipilimumab plus nivolumab, and 17 samples related to patients treated with sunitinib.
Results:
A group of tumors associated with enhancer demethylation was discovered, namely TED. TED was associated with tumors with sarcomatoid differentiation and poor clinical outcome. TED harbored TET1 promoter demethylation, activated the gene expression signature of epithelial–mesenchymal transition and IL6/JAK/STAT3 pathways, and displayed a TME characterized by both immune activation and suppressive populations, fibroblast infiltration, and endothelial depletion. In addition, TED was a predictive factor of resistance to the combination of first-line ipilimumab-nivolumab in the BIONIKK clinical trial. Finally, TED was associated with activation of specific regulons, which we also found to be predictive of resistance to immunotherapy in an independent cohort.
Conclusions:
We report on the discovery of a novel epigenetic phenotype associated with resistance to ICIs that may pave the way to better personalizing patients’ treatments.

See related commentary by Zhou and Kim, p. 1170
Data from Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer
Authors: Chopra Shalini , Trepka Kai , Sakhamuri Sasank , Carretero-González Alberto , Zhu Jun , Egusa Emily , Zhou Jie , Leung Kevin , Zhao Ning , Hooshdaran Nima , Feng Felix Y. , Wells James A. , Chou Jonathan , Evans Michael J.
Published: April 2023

AbstractPurpose:
Despite recent approvals for checkpoint inhibitors and antibody–drug conjugates targeting NECTIN4 or TROP2, metastatic bladder cancer remains incurable and new treatment strategies are urgently needed. CUB domain–containing protein 1 (CDCP1) is a cell surface protein and promising drug target for many cancers. This study aimed to determine whether CDCP1 is expressed in bladder cancer and whether CDCP1 can be targeted for treatment with radiolabeled antibodies.
Experimental Design:
CDCP1 expression was evaluated in four bladder cancer datasets (n = 1,047 biopsies). A tissue microarray of primary bladder cancer biopsies was probed for CDCP1 by IHC. CDCP1 expression was evaluated in patient-derived xenografts and cell lysates by immunoblot, flow cytometry, and saturation binding assays. Tumor detection in mouse bladder cancer models was tested using 89Zr-labeled 4A06, a monoclonal antibody targeting the ectodomain of CDCP1. 177Lu-4A06 was applied to mice bearing UMUC3 or HT-1376 xenografts to evaluate antitumor effects (CDCP1 expression in UMUC3 is 10-fold higher than HT-1376).
Results:
CDCP1 was highest in the basal/squamous subtype, and CDCP1 was expressed in 53% of primary biopsies. CDCP1 was not correlated with pathologic or tumor stage, metastatic site, or NECTIN4 and TROP2 at the mRNA or protein level. CDCP1 ranged from 105 to 106 receptors per cell. Mechanism studies showed that RAS signaling induced CDCP1 expression. 89Zr-4A06 PET detected five human bladder cancer xenografts. 177Lu-4A06 inhibited the growth of UMUC3 and HT-1376 xenografts, models with high and moderate CDCP1 expression, respectively.
Conclusions:
These data establish that CDCP1 is expressed in bladder cancer, including TROP2 and NECTIN4-null disease, and suggest that bladder cancer can be treated with CDCP1-targeted radiotherapy.
Data from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC
Authors: Patel Sonia A. , Nilsson Monique B. , Yang Yan , Le Xiuning , Tran Hai T. , Elamin Yasir Y. , Yu Xiaoxing , Zhang Fahao , Poteete Alissa , Ren Xiaoyang , Shen Li , Wang Jing , Moghaddam Seyed Javad , Cascone Tina , Curran Michael , Gibbons Don L. , Heymach John V.
Published: April 2023

AbstractPurpose:
Patients with advanced non–small cell lung cancer (NSCLC) harboring activating EGFR mutations are initially responsive to tyrosine kinase inhibitors (TKI). However, therapeutic resistance eventually emerges, often via secondary EGFR mutations or EGFR-independent mechanisms such as epithelial-to-mesenchymal transition. Treatment options after EGFR-TKI resistance are limited as anti-PD-1/PD-L1 inhibitors typically display minimal benefit. Given that IL6 is associated with worse outcomes in patients with NSCLC, we investigate whether IL6 in part contributes to this immunosuppressed phenotype.
Experimental Design:
We utilized a syngeneic genetically engineered mouse model (GEMM) of EGFR-mutant NSCLC to investigate the effects of IL6 on the tumor microenvironment and the combined efficacy of IL6 inhibition and anti-PD-1 therapy. Corresponding in vitro studies used EGFR-mutant human cell lines and clinical specimens.
Results:
We identified that EGFR-mutant tumors which have oncogene-independent acquired resistance to EGFR-TKIs were more mesenchymal and had markedly enhanced IL6 secretion. In EGFR-mutant GEMMs, IL6 depletion enhanced activation of infiltrating natural killer (NK)- and T-cell subpopulations and decreased immunosuppressive regulatory T and Th17 cell populations. Inhibition of IL6 increased NK- and T cell–mediated killing of human osimertinib-resistant EGFR-mutant NSCLC tumor cells in cell culture. IL6 blockade sensitized EGFR-mutant GEMM tumors to PD-1 inhibitors through an increase in tumor-infiltrating IFNγ+ CD8+ T cells.
Conclusions:
These data indicate that IL6 is upregulated in EGFR-mutant NSCLC tumors with acquired EGFR-TKI resistance and suppressed T- and NK-cell function. IL6 blockade enhanced antitumor immunity and efficacy of anti-PD-1 therapy warranting future clinical combinatorial investigations.
Data from Event-Free Survival as a Surrogate for Overall Survival in Gastric and Gastroesophageal Junction Adenocarcinoma: A Meta-analysis in the Neoadjuvant ± Adjuvant Setting
Authors: Wainberg Zev A. , Xie Jipan , Valderrama Adriana , Yin Lei , Zhang Shujing , Shih Chie-Schin , Bhagia Pooja , Gu Qianqian , Shitara Kohei , Janjigian Yelena Y. , Tabernero Josep
Published: April 2023

AbstractPurpose:
This study assessed the trial-level association between event-free survival (EFS) and overall survival (OS) in gastric or gastroesophageal junction (GEJ) adenocarcinoma in the neoadjuvant ± adjuvant settings.
Experimental Design:
A systematic literature review was conducted to identify randomized controlled trials (RCT) that evaluated neoadjuvant therapies with or without adjuvant therapies for gastric or GEJ adenocarcinoma. A meta-analysis was performed using weighted linear regressions of the treatment effect of OS on the treatment effect of EFS. The coefficient of determination (R²) and associated 95% confidence interval (CI) were used to evaluate the association between treatment effects of EFS and OS. The threshold used for defining good trial-level surrogacy was a correlation coefficient (R) of 0.8 or R² of 0.65, based on prior literature. Sensitivity analyses were performed to assess the robustness of the association with divergent study designs, including study population, inclusion of adjuvant therapy, and definitions of EFS and OS.
Results:
The main analysis included 16 comparisons from 15 RCTs. The log(HR) of EFS was a significant predictor of log(HR) of OS, with an estimated coefficient of 0.72 (P < 0.001) and R² = 0.75 (95% CI, 0.49–0.95), indicating that EFS was a good surrogate outcome for OS. The results of the sensitivity analyses were consistent with the primary results, with R² ranging from 0.76 to 0.89.
Conclusions:
This study suggests that EFS is a good surrogate for OS in gastric or GEJ adenocarcinoma in the neoadjuvant ± adjuvant setting.
Data from Comprehensive ctDNA Measurements Improve Prediction of Clinical Outcomes and Enable Dynamic Tracking of Disease Progression in Advanced Pancreatic Cancer
Authors: Lapin Morten , Edland Karin H. , Tjensvoll Kjersti , Oltedal Satu , Austdal Marie , Garresori Herish , Rozenholc Yves , Gilje Bjørnar , Nordgård Oddmund
Published: April 2023

AbstractPurpose:
Circulating tumor DNA (ctDNA) has emerged as a promising tumor-specific biomarker in pancreatic cancer, but current evidence of the clinical potential of ctDNA is limited. In this study, we used comprehensive detection methodology to explore the utility of longitudinal ctDNA measurements in patients with advanced pancreatic cancer.
Experimental Design:
A targeted eight-gene next-generation sequencing panel was used to detect point mutations and copy-number aberrations (CNA) in ctDNA from 324 pre-treatment and longitudinal plasma samples obtained from 56 patients with advanced pancreatic cancer. The benefit of ctDNA measurements to predict clinical outcome and track disease progression was assessed.
Results:
We detected ctDNA in 35/56 (63%) patients at baseline and found that it was an independent predictor of shorter progression-free survival (PFS) and overall survival (OS). After initiation of treatment, ctDNA levels decreased significantly before significantly increasing by the time of progression. In some patients, ctDNA persistence was observed after the first chemotherapy cycles, and it was associated with rapid disease progression and shorter OS. Longitudinal monitoring of ctDNA levels in 27 patients for whom multiple samples were available detected progression in 19 (70%) patients. The median lead time of ctDNA measurements on radiologically determined progression/time of death was 19 days (P = 0.002), compared with 6 days (P = 0.007) using carbohydrate antigen 19–9.
Conclusions:
ctDNA is an independent prognostic marker that can be used to detect treatment failure and disease progression in patients with advanced pancreatic cancer.
Supplementary Figure Legends from Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens
Authors: Rivera Victor M. , Squillace Rachel M. , Miller David , Berk Lori , Wardwell Scott D. , Ning Yaoyu , Pollock Roy , Narasimhan Narayana I. , Iuliucci John D. , Wang Frank , Clackson Tim
Published: April 2023

Supplementary Figure Legends from Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens
Supplementary Figure 2 from Inhibition of SAPK2/p38 Enhances Sensitivity to mTORC1 Inhibition by Blocking IRES-Mediated Translation Initiation in Glioblastoma
Authors: Cloninger Cheri , Bernath Andrew , Bashir Tariq , Holmes Brent , Artinian Nicholas , Ruegg Teresa , Anderson Lauren , Masri Janine , Lichtenstein Alan , Gera Joseph
Published: April 2023

PDF file - 589K
Supplementary Figure Legends from Enhanced Antitumor Effects by Chemical Modified IGb3 Analogues
Authors: Zhou Zhixia , Zhang Cai , Xia Chengfeng , Chen Wenlan , Zhu Huawei , Shang Pingping , Ma Fang , Wang Peng George , Zhang Jian , Xu Wenfang , Tian Zhigang
Published: April 2023

Supplementary Figure Legends from Enhanced Antitumor Effects by Chemical Modified IGb3 Analogues
Supplementary Figure 1A-D from Transformation-Dependent Silencing of Tumor-Selective Apoptosis-Inducing TRAIL by DNA Hypermethylation Is Antagonized by Decitabine
Authors: Lund Per , Kotova Irina , Kedinger Valérie , Khanwalkar Harshal , Voltz Emilie , Hahn William C. , Gronemeyer Hinrich
Published: April 2023

Supplementary Figure 1A-D from Transformation-Dependent Silencing of Tumor-Selective Apoptosis-Inducing TRAIL by DNA Hypermethylation Is Antagonized by Decitabine
Supplementary Figure 2 from Liposomal Delivery of MicroRNA-7–Expressing Plasmid Overcomes Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Resistance in Lung Cancer Cells
Authors: Rai Kammei , Takigawa Nagio , Ito Sachio , Kashihara Hiromi , Ichihara Eiki , Yasuda Tatsuji , Shimizu Kenji , Tanimoto Mitsune , Kiura Katsuyuki
Published: April 2023

Supplementary Figure 2 from Liposomal Delivery of MicroRNA-7–Expressing Plasmid Overcomes Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Resistance in Lung Cancer Cells
Supplementary Figure and Table Legend from Compensatory Pathways Induced by MEK Inhibition Are Effective Drug Targets for Combination Therapy against Castration-Resistant Prostate Cancer
Authors: Gioeli Daniel , Wunderlich Winfried , Sebolt-Leopold Judith , Bekiranov Stefan , Wulfkuhle Julia D. , Petricoin Emanuel F. , Conaway Mark , Weber Michael J.
Published: April 2023

Supplementary Figure and Table Legend from Compensatory Pathways Induced by MEK Inhibition Are Effective Drug Targets for Combination Therapy against Castration-Resistant Prostate Cancer
Supplementary Methods and Figure Legends 1-9 from Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin
Authors: Bhagwat Shripad V. , Gokhale Prafulla C. , Crew Andrew P. , Cooke Andy , Yao Yan , Mantis Christine , Kahler Jennifer , Workman Jennifer , Bittner Mark , Dudkin Lorina , Epstein David M. , Gibson Neil W. , Wild Robert , Arnold Lee D. , Houghton Peter J. , Pachter Jonathan A.
Published: April 2023

Supplementary Methods and Figure Legends 1-9 from Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin
Supplementary Methods, Figure Legends and Tables 1 - 2 from Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells
Authors: Caldon C. Elizabeth , Sergio C. Marcelo , Kang Jian , Muthukaruppan Anita , Boersma Marijke N. , Stone Andrew , Barraclough Jane , Lee Christine S. , Black Michael A. , Miller Lance D. , Gee Julia M. , Nicholson Rob I. , Sutherland Robert L. , Print Cristin G. , Musgrove Elizabeth A.
Published: April 2023

PDF file, 56KB.
Supplementary Figure 1 from Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells
Authors: Caldon C. Elizabeth , Sergio C. Marcelo , Kang Jian , Muthukaruppan Anita , Boersma Marijke N. , Stone Andrew , Barraclough Jane , Lee Christine S. , Black Michael A. , Miller Lance D. , Gee Julia M. , Nicholson Rob I. , Sutherland Robert L. , Print Cristin G. , Musgrove Elizabeth A.
Published: April 2023

PDF file, 929KB, Supplementary Figure 1: Cyclin E2 association with breast cancer subtype, grade, and outcome. A: Relationship between a second cyclin E2 probeset and breast cancer subtype, or histological grade. Box: upper and lower quartiles; dividing line: median. B: Relative expression of cyclin E1 and a second cyclin E2 probeset in individual tumours in breast cancer subtypes. C: Kaplan-Meier survival analysis of distant metastasis-free survival from ER-positive patients treated with endocrine therapy (n=287) and untreated ER-negative patients (n=106), using a 70% cutoff between high and low expression.
Supplementary Figure 3 from Targeting the Mitochondria Activates Two Independent Cell Death Pathways in Ovarian Cancer Stem Cells
Authors: Alvero Ayesha B. , Montagna Michele K. , Holmberg Jennie C. , Craveiro Vinicius , Brown David , Mor Gil
Published: April 2023

Supplementary Figure 3 from Targeting the Mitochondria Activates Two Independent Cell Death Pathways in Ovarian Cancer Stem Cells
Supplementary Methods, Figures 1-3 from Discovery of a Small Molecule Targeting IRA2 Deletion in Budding Yeast and Neurofibromin Loss in Malignant Peripheral Nerve Sheath Tumor Cells
Authors: Wood Matthew , Rawe Melissa , Johansson Gunnar , Pang Shu , Soderquist Ryan S. , Patel Ami V. , Nelson Sandra , Seibel William , Ratner Nancy , Sanchez Yolanda
Published: April 2023

Supplementary Methods, Figures 1-3 from Discovery of a Small Molecule Targeting IRA2 Deletion in Budding Yeast and Neurofibromin Loss in Malignant Peripheral Nerve Sheath Tumor Cells
Supplementary Methods from Sorafenib-Mediated Targeting of the AAA+ ATPase p97/VCP Leads to Disruption of the Secretory Pathway, Endoplasmic Reticulum Stress, and Hepatocellular Cancer Cell Death
Authors: Yi Ping , Higa Arisa , Taouji Said , Bexiga Mariana G. , Marza Esther , Arma Daniela , Castain Claire , Le Bail Brigitte , Simpson Jeremy C. , Rosenbaum Jean , Balabaud Charles , Bioulac-Sage Paulette , Blanc Jean-Frédéric , Chevet Eric
Published: April 2023

PDF file - 81K
Supplemental Materials and Methods and Supplementary Figures 1-3 from Discovery of a Small Molecule Targeting IRA2 Deletion in Budding Yeast and Neurofibromin Loss in Malignant Peripheral Nerve Sheath Tumor Cells
Authors: Wood Matthew , Rawe Melissa , Johansson Gunnar , Pang Shu , Soderquist Ryan S. , Patel Ami V. , Nelson Sandra , Seibel William , Ratner Nancy , Sanchez Yolanda
Published: April 2023

Supplemental Materials and Methods Supplemental Figure 1 â€" Analysis of a UC1-like compound. Supplemental Figure 2 â€" Plasmid shuffle system for high-efficiency transformation of erg6Δira2 Δ yeast cells. Supplemental Figure 3 â€" Phenotypic screening of UC1-resistant colonies.
Supplementary Figures 1-2 from Antisense Inhibition of Survivin Expression as a Cancer Therapeutic
Authors: Carrasco Rosa A. , Stamm Nancy B. , Marcusson Eric , Sandusky George , Iversen Philip , Patel Bharvin K.R.
Published: April 2023

Supplementary Figures 1-2 from Antisense Inhibition of Survivin Expression as a Cancer Therapeutic
Supplementary Figure Legends 1-3 from CYP2S1 and CYP2W1 Mediate 2-(3,4-Dimethoxyphenyl)-5-Fluorobenzothiazole (GW-610, NSC 721648) Sensitivity in Breast and Colorectal Cancer Cells
Authors: Tan Boon Shing , Tiong Kai Hung , Muruhadas Ashwin , Randhawa Nirmal , Choo Heng Lungh , Bradshaw Tracey D. , Stevens Malcolm F.G. , Leong Chee-Onn
Published: April 2023

PDF file - 64K
Supplementary Table 3 from DLK1 as a Potential Target against Cancer Stem/Progenitor Cells of Hepatocellular Carcinoma
Authors: Xu Xiao , Liu Rui-Fang , Zhang Xin , Huang Li-Yu , Chen Fei , Fei Qian-Lan , Han Ze-Guang
Published: April 2023

PDF file - 90K
Supplementary Figure 4 from Inhibition of dUTPase Induces Synthetic Lethality with Thymidylate Synthase–Targeted Therapies in Non–Small Cell Lung Cancer
Authors: Wilson Peter M. , LaBonte Melissa J. , Lenz Heinz-Josef , Mack Philip C. , Ladner Robert D.
Published: April 2023

PDF file - 274K
Supplementary Figure 2 from DLK1 as a Potential Target against Cancer Stem/Progenitor Cells of Hepatocellular Carcinoma
Authors: Xu Xiao , Liu Rui-Fang , Zhang Xin , Huang Li-Yu , Chen Fei , Fei Qian-Lan , Han Ze-Guang
Published: April 2023

PDF file - 111K
Supplementary Table 1 from PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors
Authors: Janku Filip , Tsimberidou Apostolia M. , Garrido-Laguna Ignacio , Wang Xuemei , Luthra Rajyalakshmi , Hong David S. , Naing Aung , Falchook Gerald S. , Moroney John W. , Piha-Paul Sarina A. , Wheler Jennifer J. , Moulder Stacy L. , Fu Siqing , Kurzrock Razelle
Published: April 2023

Supplementary Table 1 from PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors
Supplementary Figures 1-7 from Carfilzomib Interacts Synergistically with Histone Deacetylase Inhibitors in Mantle Cell Lymphoma Cells In Vitro and In Vivo
Authors: Dasmahapatra Girija , Lembersky Dmitry , Son Minkyeong P. , Attkisson Elisa , Dent Paul , Fisher Richard I. , Friedberg Jonathan W. , Grant Steven
Published: April 2023

PDF file - 284K
Supplementary Figure Legends 1-7 from Carfilzomib Interacts Synergistically with Histone Deacetylase Inhibitors in Mantle Cell Lymphoma Cells In Vitro and In Vivo
Authors: Dasmahapatra Girija , Lembersky Dmitry , Son Minkyeong P. , Attkisson Elisa , Dent Paul , Fisher Richard I. , Friedberg Jonathan W. , Grant Steven
Published: April 2023

PDF file - 117K
Supplementary Table 3 from Drug Resistance to Inhibitors of the Human Double Minute-2 E3 Ligase Is Mediated by Point Mutations of p53, but Can Be Overcome with the p53 Targeting Agent RITA
Authors: Jones Richard J. , Bjorklund Chad C. , Baladandayuthapani Veerabhadran , Kuhn Deborah J. , Orlowski Robert Z.
Published: April 2023

PDF file, 53K, p53 mutations in MI63R and NutlinR cells.
Supplementary Figure 1 from Epithelial–Mesenchymal Transition and Stem Cell Markers in Patients with HER2-Positive Metastatic Breast Cancer
Authors: Giordano Antonio , Gao Hui , Anfossi Simone , Cohen Evan , Mego Michal , Lee Bang-Ning , Tin Sanda , De Laurentiis Michele , Parker Charla A. , Alvarez Ricardo H. , Valero Vicente , Ueno Naoto T. , De Placido Sabino , Mani Sendurai A. , Esteva Francisco J. , Cristofanilli Massimo , Reuben James M.
Published: April 2023

PDF file - 64K, Gene expression levels of EMT-TFs in the tested cell lines (HMLE, HMLE-TWIST, MCF-7, BT-474, SKBR-3, MDA-MB-231)
Supplementary Table 2 from Dll4-Fc, an Inhibitor of Dll4-Notch Signaling, Suppresses Liver Metastasis of Small Cell Lung Cancer Cells through the Downregulation of the NF-κB Activity
Authors: Kuramoto Takuya , Goto Hisatsugu , Mitsuhashi Atsushi , Tabata Sho , Ogawa Hirohisa , Uehara Hisanori , Saijo Atsuro , Kakiuchi Soji , Maekawa Yoichi , Yasutomo Koji , Hanibuchi Masaki , Akiyama Shin-ichi , Sone Saburo , Nishioka Yasuhiko
Published: April 2023

PDF file - 69K, Dll4-Fc suppresses genes-associated with metastasis in SCLC cells
Supplementary Methods and Table Legends from RSK2Ser227 at N-Terminal Kinase Domain Is a Potential Therapeutic Target for Multiple Myeloma
Authors: Shimura Yuji , Kuroda Junya , Ri Masaki , Nagoshi Hisao , Yamamoto-Sugitani Mio , Kobayashi Tsutomu , Kiyota Miki , Nakayama Ryuko , Mizutani Shinsuke , Chinen Yoshiaki , Sakamoto Natsumi , Matsumoto Yosuke , Horiike Shigeo , Shiotsu Yukimasa , Iida Shinsuke , Taniwaki Masafumi
Published: April 2023

PDF file - 141K
Supplementary Figure 1 from Impact of APE1/Ref-1 Redox Inhibition on Pancreatic Tumor Growth
Authors: Fishel Melissa L. , Jiang Yanlin , Rajeshkumar N.V. , Scandura Glenda , Sinn Anthony L. , He Ying , Shen Changyu , Jones David R. , Pollok Karen E. , Ivan Mircea , Maitra Anirban , Kelley Mark R.
Published: April 2023

Supplementary Figure 1 from Impact of APE1/Ref-1 Redox Inhibition on Pancreatic Tumor Growth
Supplementary Figures 1-5 from In Vivo Activity of Combined PI3K/mTOR and MEK Inhibition in a KrasG12D;Pten Deletion Mouse Model of Ovarian Cancer
Authors: Kinross Kathryn M. , Brown Daniel V. , Kleinschmidt Margarete , Jackson Susan , Christensen James , Cullinane Carleen , Hicks Rodney J. , Johnstone Ricky W. , McArthur Grant A.
Published: April 2023

Supplementary Figures 1-5 from In Vivo Activity of Combined PI3K/mTOR and MEK Inhibition in a KrasG12D;Pten Deletion Mouse Model of Ovarian Cancer
Supplementary Figure 1 from Human Monoclonal Antibody Fragments Binding to Insulin-like Growth Factors I and II with Picomolar Affinity
Authors: Zhao Qi , Feng Yang , Zhu Zhongyu , Dimitrov Dimiter S.
Published: April 2023

PDF file - 662K
Supplementary Figure 1 from Transcription Factor Stat5 Knockdown Enhances Androgen Receptor Degradation and Delays Castration-Resistant Prostate Cancer Progression In vivo
Authors: Thomas Christian , Zoubeidi Amina , Kuruma Hidetoshi , Fazli Ladan , Lamoureux Francois , Beraldi Eliana , Monia Brett P. , MacLeod A. Robert , Thüroff Joachim W. , Gleave Martin E.
Published: April 2023

Supplementary Figure 1 from Transcription Factor Stat5 Knockdown Enhances Androgen Receptor Degradation and Delays Castration-Resistant Prostate Cancer Progression In vivo
Supplementary Figure 1 from Comprehensive Predictive Biomarker Analysis for MEK Inhibitor GSK1120212
Authors: Jing Junping , Greshock Joel , Holbrook Joanna Dawn , Gilmartin Aidan , Zhang Xiping , McNeil Elizabeth , Conway Theresa , Moy Christopher , Laquerre Sylvie , Bachman Kurt , Wooster Richard , Degenhardt Yan
Published: April 2023

PDF file - 31K
Supplementary Figures 1-4, Tables 1-8 from GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway
Authors: Wallin Jeffrey J. , Edgar Kyle A. , Guan Jane , Berry Megan , Prior Wei Wei , Lee Leslie , Lesnick John D. , Lewis Cristina , Nonomiya Jim , Pang Jodie , Salphati Laurent , Olivero Alan G. , Sutherlin Daniel P. , O'Brien Carol , Spoerke Jill M. , Patel Sonal , Lensun Letitia , Kassees Robert , Ross Leanne , Lackner Mark R. , Sampath Deepak , Belvin Marcia , Friedman Lori S.
Published: April 2023

PDF file - 894K
Supplementary Table 1 from Active Efflux of Dasatinib from the Brain Limits Efficacy against Murine Glioblastoma: Broad Implications for the Clinical Use of Molecularly Targeted Agents
Authors: Agarwal Sagar , Mittapalli Rajendar K. , Zellmer David M. , Gallardo Jose L. , Donelson Randy , Seiler Charlie , Decker Stacy A. , SantaCruz Karen S. , Pokorny Jenny L. , Sarkaria Jann N. , Elmquist William F. , Ohlfest John R.
Published: April 2023

PDF file, 71K, Pharmacokinetic Parameters in WT and TKO Mice after Oral Dosing with 15 mg/kg Dasatinib (Data presented as Mean � S.E. of Estimate).
Supplementary Methods, Figures 1-4 from Histone Deacetylase Cytoplasmic Trapping by a Novel Fluorescent HDAC Inhibitor
Authors: Kong Yali , Jung Mira , Wang Kan , Grindrod Scott , Velena Alfredo , Lee Sung A. , Dakshanamurthy Sivanesan , Yang Yonghong , Miessau Matthew , Zheng Chaoyi , Dritschilo Anatoly , Brown Milton L.
Published: April 2023

Supplementary Methods, Figures 1-4 from Histone Deacetylase Cytoplasmic Trapping by a Novel Fluorescent HDAC Inhibitor
Supplementary Figure 3 from Pancratistatin Selectively Targets Cancer Cell Mitochondria and Reduces Growth of Human Colon Tumor Xenografts
Authors: Griffin Carly , Karnik Aditya , McNulty James , Pandey Siyaram
Published: April 2023

Supplementary Figure 3 from Pancratistatin Selectively Targets Cancer Cell Mitochondria and Reduces Growth of Human Colon Tumor Xenografts
Supplementary Figure 1 from Pancratistatin Selectively Targets Cancer Cell Mitochondria and Reduces Growth of Human Colon Tumor Xenografts
Authors: Griffin Carly , Karnik Aditya , McNulty James , Pandey Siyaram
Published: April 2023

Supplementary Figure 1 from Pancratistatin Selectively Targets Cancer Cell Mitochondria and Reduces Growth of Human Colon Tumor Xenografts
Supplementary Figure 6 from Cancer Cells Cyclically Lose and Regain Drug-Resistant Highly Tumorigenic Features Characteristic of a Cancer Stem-like Phenotype
Authors: He Kaijie , Xu Tong , Goldkorn Amir
Published: April 2023

Supplementary Figure 6 from Cancer Cells Cyclically Lose and Regain Drug-Resistant Highly Tumorigenic Features Characteristic of a Cancer Stem-like Phenotype
Supplementary Methods and Figure Legend from REST Is a Novel Prognostic Factor and Therapeutic Target for Medulloblastoma
Authors: Taylor Pete , Fangusaro Jason , Rajaram Veena , Goldman Stewart , Helenowski Irene B. , MacDonald Tobey , Hasselblatt Martin , Riedemann Lars , Laureano Alvaro , Cooper Laurence , Gopalakrishnan Vidya
Published: April 2023

PDF file, 73KB.
Supplementary Figure 1 from REST Is a Novel Prognostic Factor and Therapeutic Target for Medulloblastoma
Authors: Taylor Pete , Fangusaro Jason , Rajaram Veena , Goldman Stewart , Helenowski Irene B. , MacDonald Tobey , Hasselblatt Martin , Riedemann Lars , Laureano Alvaro , Cooper Laurence , Gopalakrishnan Vidya
Published: April 2023

PDF file, 169KB, Measurement of Syn1 expression following SAHA treatment of murine NSC-M and NSC-MR cells.
Supplementary Figure 1 from Growth Inhibition of Ovarian Tumor–Initiating Cells by Niclosamide
Authors: Yo Yi-Te , Lin Ya-Wen , Wang Yu-Chi , Balch Curt , Huang Rui-Lan , Chan Michael W.Y. , Sytwu Huey-Kang , Chen Chi-Kuan , Chang Cheng-Chang , Nephew Kenneth P. , Huang Tim , Yu Mu-Hsien , Lai Hung-Cheng
Published: April 2023

PDF file, 1369KB, A, pretreatment of cells with the ABCG2 inhibitor GF120918 essentially eliminated the SP fraction of CP70 ovarian cancer cells (right panel). B, ovarian cancer CP70 SP spheroid-forming cells ("CP70sps cells"). CP70 SP cells were cultured in ultra low coating culture dishes, with anchorage-independent cells forming a spheroid morphology (CP70sps, 400�).
Supplementary Figure 3 from Genetic Variation That Predicts Platinum Sensitivity Reveals the Role of miR-193b* in Chemotherapeutic Susceptibility
Authors: Ziliak Dana , Gamazon Eric R. , LaCroix Bonnie , Kyung Im Hae , Wen Yujia , Huang Rong Stephanie
Published: April 2023

PDF file, 88K, The relationship between -log10GI50 of platinum agents and the expression of miR-193b* in 7 ovarian cancer cell lines.
Supplementary Table 1 from High TUBB3 Expression, an Independent Prognostic Marker in Patients with Early Non–Small Cell Lung Cancer Treated by Preoperative Chemotherapy, Is Regulated by K-Ras Signaling Pathway
Authors: Levallet Guénaëlle , Bergot Emmanuel , Antoine Martine , Creveuil Christian , Santos Adriana O. , Beau-Faller Michelle , de Fraipont Florence , Brambilla Elisabeth , Levallet Jérôme , Morin Franck , Westeel Virginie , Wislez Marie , Quoix Elisabeth , Debieuvre Didier , Dubois Fatéméh , Rouquette Isabelle , Pujol Jean-Louis , Moro-Sibilot Denis , Camonis Jacques , Zalcman Gérard
Published: April 2023

PDF file - 56K
Supplementary Figure 4 from High TUBB3 Expression, an Independent Prognostic Marker in Patients with Early Non–Small Cell Lung Cancer Treated by Preoperative Chemotherapy, Is Regulated by K-Ras Signaling Pathway
Authors: Levallet Guénaëlle , Bergot Emmanuel , Antoine Martine , Creveuil Christian , Santos Adriana O. , Beau-Faller Michelle , de Fraipont Florence , Brambilla Elisabeth , Levallet Jérôme , Morin Franck , Westeel Virginie , Wislez Marie , Quoix Elisabeth , Debieuvre Didier , Dubois Fatéméh , Rouquette Isabelle , Pujol Jean-Louis , Moro-Sibilot Denis , Camonis Jacques , Zalcman Gérard
Published: April 2023

PDF file - 352K, TUBB3 mRNA and protein expression according to K-RAs Si-RNA
Supplementary Figure 1 from High TUBB3 Expression, an Independent Prognostic Marker in Patients with Early Non–Small Cell Lung Cancer Treated by Preoperative Chemotherapy, Is Regulated by K-Ras Signaling Pathway
Authors: Levallet Guénaëlle , Bergot Emmanuel , Antoine Martine , Creveuil Christian , Santos Adriana O. , Beau-Faller Michelle , de Fraipont Florence , Brambilla Elisabeth , Levallet Jérôme , Morin Franck , Westeel Virginie , Wislez Marie , Quoix Elisabeth , Debieuvre Didier , Dubois Fatéméh , Rouquette Isabelle , Pujol Jean-Louis , Moro-Sibilot Denis , Camonis Jacques , Zalcman Gérard
Published: April 2023

PDF file - 60K, Flow-Chart
Supplementary Figure 6 from Activity of a Py–Im Polyamide Targeted to the Estrogen Response Element
Authors: Nickols Nicholas G. , Szablowski Jerzy O. , Hargrove Amanda E. , Li Benjamin C. , Raskatov Jevgenij A. , Dervan Peter B.
Published: April 2023

PDF File - 24K, Serum concentrations of 1 after subcutaneous injection (120 nmol) into C57BL/6 mice.
Supplementary Figure 5 from Breakdown of the FLT3-ITD/STAT5 Axis and Synergistic Apoptosis Induction by the Histone Deacetylase Inhibitor Panobinostat and FLT3-Specific Inhibitors
Authors: Pietschmann Kristin , Bolck Hella Anna , Buchwald Marc , Spielberg Steffi , Polzer Harald , Spiekermann Karsten , Bug Gesine , Heinzel Thorsten , Böhmer Frank-Dietmar , Krämer Oliver H.
Published: April 2023

PDF file, 54K, LBH589 and AC220 specifically induce degradation of STAT5 in leukemic cells expressing FLT3-ITD.
Supplementary Table 1 from Identification of Docetaxel Resistance Genes in Castration-Resistant Prostate Cancer
Authors: Marín-Aguilera Mercedes , Codony-Servat Jordi , Kalko Susana G. , Fernández Pedro L. , Bermudo Raquel , Buxo Elvira , Ribal María José , Gascón Pedro , Mellado Begoña
Published: April 2023

PDF file - 189K
Supplementary Figure 1 from Stromal Platelet-Derived Growth Factor Receptor α (PDGFRα) Provides a Therapeutic Target Independent of Tumor Cell PDGFRα Expression in Lung Cancer Xenografts
Authors: Gerber David E. , Gupta Puja , Dellinger Michael T. , Toombs Jason E. , Peyton Michael , Duignan Inga , Malaby Jennifer , Bailey Timothy , Burns Colleen , Brekken Rolf A. , Loizos Nick
Published: April 2023

PDF file, 156K, NSCLC cell line expression of PDGFRα.
Supplementary Figure 2 from Dibenzophenanthridines as Inhibitors of Glutaminase C and Cancer Cell Proliferation
Authors: Katt William P. , Ramachandran Sekar , Erickson Jon W. , Cerione Richard A.
Published: April 2023

PDF file, 48KB, Graph showing 968 potency at multiple doses when 968 is added to GAC before or after inorganic phosphate.
Supplementary Figure 1 from Dibenzophenanthridines as Inhibitors of Glutaminase C and Cancer Cell Proliferation
Authors: Katt William P. , Ramachandran Sekar , Erickson Jon W. , Cerione Richard A.
Published: April 2023

PDF file, 118KB, Graph showing dependence of 968 activity upon order in which GAC is exposed to assay reagents.
Supplementary Table 3 from Gene Expression Profile in Response to Doxorubicin–Rapamycin Combined Treatment of HER-2–Overexpressing Human Mammary Epithelial Cell Lines
Authors: Trapé Adriana Priscila , Katayama Maria Lucia Hirata , Roela Rosimeire Aparecida , Brentani Helena , Ravacci Graziela Rosa , de Araujo Lima Leandro , Brentani Maria Mitzi
Published: April 2023

PDF file - 79K
Supplementary Table 1 from Gene Expression Profile in Response to Doxorubicin–Rapamycin Combined Treatment of HER-2–Overexpressing Human Mammary Epithelial Cell Lines
Authors: Trapé Adriana Priscila , Katayama Maria Lucia Hirata , Roela Rosimeire Aparecida , Brentani Helena , Ravacci Graziela Rosa , de Araujo Lima Leandro , Brentani Maria Mitzi
Published: April 2023

PDF file - 83K
Supplementary Figure 3 from Gene Expression Profile in Response to Doxorubicin–Rapamycin Combined Treatment of HER-2–Overexpressing Human Mammary Epithelial Cell Lines
Authors: Trapé Adriana Priscila , Katayama Maria Lucia Hirata , Roela Rosimeire Aparecida , Brentani Helena , Ravacci Graziela Rosa , de Araujo Lima Leandro , Brentani Maria Mitzi
Published: April 2023

PDF file - 793K
Supplementary Methods and Figure Legend from Dual Programmed Cell Death Pathways Induced by p53 Transactivation Overcome Resistance to Oncolytic Adenovirus in Human Osteosarcoma Cells
Authors: Hasei Joe , Sasaki Tsuyoshi , Tazawa Hiroshi , Osaki Shuhei , Yamakawa Yasuaki , Kunisada Toshiyuki , Yoshida Aki , Hashimoto Yuuri , Onishi Teppei , Uno Futoshi , Kagawa Shunsuke , Urata Yasuo , Ozaki Toshifumi , Fujiwara Toshiyoshi
Published: April 2023

PDF file - 99K
Supplementary Figure 5 from Low Levels of Circulating Estrogen Sensitize PTEN-Null Endometrial Tumors to PARP Inhibition In Vivo
Authors: Janzen Deanna M. , Paik Daniel Y. , Rosales Miguel A. , Yep Brian , Cheng Donghui , Witte Owen N. , Kayadibi Huseyin , Ryan Christopher M. , Jung Michael E. , Faull Kym , Memarzadeh Sanaz
Published: April 2023

PDF file - 322K, Figure S5. Levels of Rad51 transcript were higher in estrogen supplemented PTEN-null endometrial epithelia.
Supplementary Figure 2A from Antitumor Effect of SIRT1 Inhibition in Human HCC Tumor Models In Vitro and In Vivo
Authors: Portmann Simone , Fahrner René , Lechleiter Antje , Keogh Adrian , Overney Sarah , Laemmle Alexander , Mikami Kei , Montani Matteo , Tschan Mario P. , Candinas Daniel , Stroka Deborah
Published: April 2023

PDF file - 307K, SIRT1 knockdown in Hep3B and HuH7 cells
Supplementary Figure 4 from miR-148b Functions as a Tumor Suppressor in Pancreatic Cancer by Targeting AMPKα1
Authors: Zhao Gang , Zhang Jun-Gang , Liu Yang , Qin Qi , Wang Bo , Tian Kui , Liu Lin , Li Xiang , Niu Yi , Deng Shi-Chang , Wang Chun-You
Published: April 2023

PDF file - 1881K, Figure S4. LV-shAMPKα1 suppresses tumourigenicity in nude mouse xenograft model.
Supplementary Figure 2 from miR-148b Functions as a Tumor Suppressor in Pancreatic Cancer by Targeting AMPKα1
Authors: Zhao Gang , Zhang Jun-Gang , Liu Yang , Qin Qi , Wang Bo , Tian Kui , Liu Lin , Li Xiang , Niu Yi , Deng Shi-Chang , Wang Chun-You
Published: April 2023

PDF file - 3019K, Figure S2. MiR-148b suppresses tumourigenicity in nude mouse xenograft model.
Supplementary Table 2 from Antitumor Activity of Src Inhibitor Saracatinib (AZD-0530) in Preclinical Models of Biliary Tract Carcinomas
Authors: Cavalloni Giuliana , Peraldo-Neia Caterina , Sarotto Ivana , Gammaitoni Loretta , Migliardi Giorgia , Soster Marco , Marchiò Serena , Aglietta Massimo , Leone Francesco
Published: April 2023

PDF file, 548KB, Differentially expressed genes obtained in in vitro and in vivo experiments; Saracatinib-deregulated genes both in vitro and in vivo models of BTC.
Supplementary Figure Legend from Small-Molecule Inhibitors of USP1 Target ID1 Degradation in Leukemic Cells
Authors: Mistry Helena , Hsieh Grace , Buhrlage Sara J. , Huang Min , Park Eunmi , Cuny Gregory D. , Galinsky Ilene , Stone Richard M. , Gray Nathanael S. , D'Andrea Alan D. , Parmar Kalindi
Published: April 2023

PDF - 90KB, Legends for Supplemental Figures 1 through 6.